Stock performance snapshot
Natera (NTRA) has drawn investor attention after a period of weaker share performance, with the stock down about 7% over the past week, 14% over the past month, and 22% in the past 3 months.
See our latest analysis for Natera.
That weak recent share price momentum contrasts with a 26.89% 1 year total shareholder return and a very large 228.98% 3 year total shareholder return. This suggests the latest pullback may reflect shifting sentiment around growth prospects and risk rather than a simple break in the longer term story.
If you are weighing what else could be shaping the future of healthcare and diagnostics, it is worth scanning a focused list of 34 healthcare AI stocks for fresh ideas beyond Natera.
So with Natera trading at a discount to both some intrinsic estimates and analyst price targets after a sharp pullback, is the recent weakness a potential entry point, or are markets already factoring in the company’s future growth?
Most Popular Narrative: 29.9% Undervalued
The most followed narrative on Natera pegs fair value at $260.65 per share, well above the last close of $182.65, and anchors that view in how molecular diagnostics could shape the business over time.
Increasing adoption and acceptance of advanced molecular diagnostics is driving sustained volume and revenue growth across Natera's diversified portfolio, with significant headroom remaining for further penetration, particularly in oncology (Signatera) and organ health (Prospera); this will likely boost top-line revenue.
Expanding clinical validation through large-scale trials (DARE, IMvigor011, PROCEED/FIND, etc.) and broadening indications is expected to lead to further payer adoption and reimbursement, especially for new tumor types and expanded Medicare coverage; this should drive higher ASPs and gross margins.
Curious what kind of revenue ramp and margin shift sit behind that fair value, and how long earnings are modeled to take to turn positive and build from there? The narrative ties together projected top line growth, improving profitability, and a future earnings multiple that is far above typical sector levels, all translated back to today using a specific discount rate.
Result: Fair Value of $260.65 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on continued trial success and reimbursement support, while high R&D and SG&A spending could keep profitability under pressure for longer than expected.
Find out about the key risks to this Natera narrative.
Another way to look at value
While the analyst narrative and our own fair value estimate point to Natera trading below intrinsic value, the current P/S of 11.2x is above the US Biotechs industry at 10.8x and the 8.8x fair ratio. That premium suggests there is less margin for error if growth or margins fall short.
See what the numbers say about this price in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
After all this, do you feel the market is being cautious or simply overlooking something? Move quickly, review the positives for yourself, and weigh up the 3 key rewards.
Looking for more investment ideas?
If you stop with just one stock, you could miss opportunities that fit your goals even better, so widen your search now using focused screeners built for stock pickers.
- Zero in on potential mispriced opportunities by checking stocks flagged as 61 high quality undervalued stocks that may warrant a closer look.
- Prioritise resilience and sleep better at night by scanning 67 resilient stocks with low risk scores that score well on stability.
- Get ahead of the crowd by reviewing a screener containing 26 high quality undiscovered gems before they attract wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com